Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TCA-101 by TCR Cure Biopharma Technology for Endometrial Cancer: Likelihood of Approval
TCA-101 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Endometrial Cancer. According to...
TCA-101 by TCR Cure Biopharma Technology for Solid Tumor: Likelihood of Approval
TCA-101 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Solid Tumor. According to...
EBV-Specific Anti-PD1 TCR-T Cells by TCR Cure Biopharma Technology for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
EBV-Specific Anti-PD1 TCR-T Cells is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Recurrent...
A-103 by TCR Cure Biopharma Technology for Solid Tumor: Likelihood of Approval
A-103 is under clinical development by TCR Cure Biopharma Technology and currently in Phase I for Solid Tumor. According to...
A-103 by TCR Cure Biopharma Technology for Testicular Cancer: Likelihood of Approval
A-103 is under clinical development by TCR Cure Biopharma Technology and currently in Phase I for Testicular Cancer. According to...
A-103 by TCR Cure Biopharma Technology for Lung Cancer: Likelihood of Approval
A-103 is under clinical development by TCR Cure Biopharma Technology and currently in Phase I for Lung Cancer. According to...
IL13R alpha 2 CAR-T by TCR Cure Biopharma Technology for Glioma: Likelihood of Approval
IL13R alpha 2 CAR-T is under clinical development by TCR Cure Biopharma Technology and currently in Phase I for Glioma....